MINNEAPOLIS, April 17, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX-V:DMA) (OTCQB:DMCAF), today announced the issuance of 2,551,000 stock options to various officers and directors of the Company. The options were issued at $0.56 per share and have a ten-year term.
The options were granted under the Company's Stock Option Plan and are part of the Company's long term incentive/retention plan for employees. The option issuance is subject to the approval of the TSX Venture Exchange.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica's shares are listed on the TSX Venture Exchange under the trading symbol "DMA" and on the OTCQB under the trading symbol "DMCAF". For more information, please visit www.diamedica.com. Follow us on social media ? Twitter, LinkedIn.
Contact:
Paul Papi Vice President of Business Development DiaMedica Therapeutics Inc. Phone: (617) 899-5941 [email protected]
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or "the Company") and certain of its officers....
ShipSaving, a fast-growing shipping platform recognized in the 2023 Deloitte Technology Fast 500tm, proudly announces a groundbreaking development as the first multi-carrier shipping company to offer UPS no-label shipping. This innovative feature...
Grand Peak Capital Corp. ("Grand Peak" or the "Company") is pleased to announce that, further to its news release of March 7, 2024, it has closed its non-brokered private placement and issued a total of 50,000,000 common shares at a price of CAD...
Isabella Bank Corporation (the "Company") reported first quarter 2024 net income of $3.1 million or $0.42 per diluted share compared to $5.3 million or $0.70 per diluted share in the same quarter of 2023.
FIRST QUARTER 2024 HIGHLIGHTS (compared to...
Banco Latinoamericano de Comercio Exterior, S.A. ("Bladex" or the "Bank"), announced today its Board of Directors' approval of a quarterly cash dividend of US$0.50 per share corresponding to the first quarter of 2024.
The cash dividend is payable...
TSX VENTURE COMPANIES
BULLETIN V2024-1134
GOLD79 MINES LTD. ("AUU")BULLETIN TYPE: ConsolidationBULLETIN DATE: April 18, 2024TSX Venture Tier 2 Company
Pursuant to a resolution passed by directors on April 2, 2024, the Company has consolidated its...
